EUVIMEDEUVIMED entdecken
Crossref

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018–2020

James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, Brune Akrich, C Andrew DeRyke, Katherine Young, Mary R Motyl, Stephen P Hawser, Daniel F Sahm

Journal of Medical Microbiology · 2023

DOI: 10.1099/jmm.0.001645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2023. Verfasst von James A Karlowsky und 8 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Schaumburg, IL, 60173, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Pseudomonas Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Piperacillin/tazobactam and carbapenems are important agents for the treatment of serious Gram-negative infections in hospitalized patients. Resistance to both agents is a significant concern in clinical isolates of Enterobacterales and Pseudomonas aeruginosa ; new agents with improved activity are needed. Gap Statement. Publication of current, region-specific data describing the in vitro activity of newer agents such as imipenem/relebactam (IMR) against piperacillin/tazobactam-resistant and carbapenem-resistant Enterobacterales and P. aeruginosa are needed to support their clinical use.

Aim

To describe the in vitro activity of IMR against non- Morganellaceae Enterobacterales (NME) and P. aeruginosa isolated from bloodstream, intra-abdominal and urinary tract infection samples by hospital laboratories in Western Europe with a focus on the activity of IMR against piperacillin/tazobactam-resistant and meropenem-resistant isolates. Methodology. From 2018 to 2020, 29 hospital laboratories in six countries in Western Europe participated in the SMART global surveillance programme and contributed 9487 NME and 1004 P . aeruginosa isolates. MICs were determined by CLSI broth microdilution testing and interpreted by EUCAST (2021) breakpoints. β-Lactamase genes were identified in selected isolate subsets (2018–2020) and oprD sequenced in molecularly characterized P. aeruginosa (2020).

Results

IMR (99.4 % susceptible), amikacin (98.0 %), meropenem (97.7 %) and imipenem (97.6 %) were the most active agents against NME; 83.1 % of NME were piperacillin/tazobactam-susceptible. Relebactam increased imipenem susceptibility of NME from Italy by 8.3 %, from Portugal by 2.9 %, and from France, Germany, Spain and the UK by

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsPseudomonas InfectionsHumansMeropenemPseudomonas aeruginosaAmikacinAnti-Bacterial AgentsImipenemPiperacillin, Tazobactam Drug CombinationEuropeMicrobial Sensitivity TestsCephalosporinsAzabicyclo Compounds

Stichwörter der Autor:innen

Gram-negativeSMARTWestern Europeimipenem/relebactamsurveillance

Substanzen

MeropenemAmikacinAnti-Bacterial AgentsImipenemPiperacillin, Tazobactam Drug CombinationCephalosporinsrelebactamAzabicyclo Compounds

Autor:innen und Institutionen

  • IHMA, Schaumburg, IL, 60173, USA.
  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, R3E 0J9, Canada.
  • Merck & Co., Inc, Rahway, NJ 07033, USA.
  • MSD, Puteaux, 92800, France.
  • IHMA, Rte. de l'Ile-au-Bois 1A, 1870 Monthey, Switzerland.

Förderung

  • Merck

Zitieren

APA

Karlowsky, J. A., Lob, S. H., Siddiqui, F., Akrich, B., DeRyke, C. A., Young, K., Motyl, M. R., Hawser, S. P., & Sahm, D. F. (2023). In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018–2020. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001645

Vancouver

Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, et al. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018–2020. Journal of Medical Microbiology. 2023. doi:10.1099/jmm.0.001645

BibTeX
@article{Karlowsky2023,
  author = {Karlowsky, James A and Lob, Sibylle H and Siddiqui, Fakhar and Akrich, Brune and DeRyke, C Andrew and Young, Katherine and Motyl, Mary R and Hawser, Stephen P and Sahm, Daniel F},
  title = {In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018–2020},
  journal = {Journal of Medical Microbiology},
  year = {2023},
  doi = {10.1099/jmm.0.001645}
}
Kostenlos starten →